Pilot study of intravenous nicotine effects on cognitive performance in schizophrenia

Schizophr Res. 2013 Oct;150(1):323-4. doi: 10.1016/j.schres.2013.07.045. Epub 2013 Aug 13.

Authors

Douglas L Boggs¹, Mohini Ranganathan, R Andrew Sewell, Steven Madonick, Deepak Cyril D'Souza

Affiliation

¹ Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA; Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA. Electronic address: douglas.boggs@yale.edu.

PMID: 23953216
DOI: 10.1016/j.schres.2013.07.045

No abstract available

Publication types

Clinical Trial
Letter
Randomized Controlled Trial

MeSH terms

Cognition Disorders / drug therapy*
Cognition Disorders / etiology
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Injections, Intravenous
Male
Neuropsychological Tests
Nicotine / administration & dosage*
Nicotinic Agonists / administration & dosage*
Pilot Projects
Psychiatric Status Rating Scales
Schizophrenia / complications
Time Factors

Substances

Nicotinic Agonists
Nicotine